Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Titan Pharmaceuticals Announces That Novartis Licenses Iloperidone To Vanda Pharmaceuticals Vanda to Complete Iloperidone Development SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire-FirstCall/...
Titan Initiates Phase II Clinical Studies of Pivanex(R) in Leukemia and Melanoma Patient Enrollment in Randomized Phase IIb Study in Lung Cancer Complete SOUTH SAN FRANCISCO, Calif., May 24...
Titan Announces Pivanex(R) Is Active Against Cancer-Related Genes Data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO...
Titan Reports Third Quarter 2003 Results SOUTH SAN FRANCISCO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. today reported financial results for the third quarter and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
